Publications by authors named "Edward Moler"

Claim this Profile
A
An exploratory retrospective assessment of a quantitative measure of diabetes risk: medical management and patient impact in a primary care setting.
Maureen R Courtney, Edward J Moler, John A Osborne, Geoff Whitney, Scott E Conard

Diabetes Metab Syndr Obes· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of risk stratification for preventing type 2 diabetes using a multi-marker diabetes risk score.
Sean D Sullivan, Louis P Garrison, Harald Rinde, Janice Kolberg, Edward J Moler

J Med Econ· January 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of accuracy of diabetes risk score and components of the metabolic syndrome in assessing risk of incident type 2 diabetes in Inter99 cohort.
Tracy B Shafizadeh, Edward J Moler, Janice A Kolberg, Uyen Thao Nguyen, Torben Hansen

PLoS One· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Metabolic syndrome components are associated with future medical costs independent of cardiovascular hospitalization and incident diabetes.
Gregory A Nichols, Edward J Moler

Metab Syndr Relat Disord· April 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Diabetes incidence for all possible combinations of metabolic syndrome components.
Gregory A Nichols, Edward J Moler

Diabetes Res Clin Pract· October 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of a type 2 diabetes risk model from a panel of serum biomarkers from the Inter99 cohort.
Janice A Kolberg, Torben Jørgensen, Robert W Gerwien, Sarah Hamren, Michael P McKenna, Edward Moler

Diabetes Care· July 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Validation of a multimarker model for assessing risk of type 2 diabetes from a five-year prospective study of 6784 Danish people (Inter99).
Mickey Urdea, Janice Kolberg, Judith Wilber, Robert Gerwien, Edward Moler

J Diabetes Sci Technol· July 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CHIR-124, a novel potent inhibitor of Chk1, potentiates the cytotoxicity of topoisomerase I poisons in vitro and in vivo.
Archie N Tse, Katherine G Rendahl, Tahir Sheikh, Haider Cheema, Kim Aardalen, Edward J Moler

Clin Cancer Res· January 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of a screening assay for surrogate markers of CHK1 inhibitor-induced cell cycle release.
Christie P Fanton, Michael W Rowe, Edward J Moler, Marjorie Ison-Dugenny, Susan K De Long

J Biomol Screen· October 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis